Skip to main content

Table 3 Univariate and multivariate analysis of OS

From: Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

Variable (comparator) Overall survival
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Early ir-fatigue
 Yes vs no 2.63 (1.83–3.77) < 0.0001 2.32 (1.59–3.38) < 0.0001
Sex
 Male vs female 1.41 (0.97–2.05) 0.0669
Age at diagnosis
 Elderly vs non-elderly 1.35 (0.96–1.89) 0.0758
Primary tumor (melanoma)
 NSCLC 2.24 (1.52–3.28) < 0.0001 1.72 (1.14–2.60) 0.0095
 Renal cell carcinoma 1.62 (0.99–2.63) 0.0518 1.40 (0.82–2.37) 0.2101
 Others 0.74 (0.10–5.38) 0.7679 0.58 (0.07–4.29) 0.5992
Treatment line
 Non-first vs first 1.58 (1.08–2.31) 0.0170 1.33 (0.88–2.01) 0.1717